Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
“Finalizing our exclusive agreement with EVERSANA is a transformative milestone as we prepare and plan to bring LYMPHIR to market in Q4 2025,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. “As a lean and strategically focused organization, this agreement allows us to significantly extend our commercial capabilities by leveraging EVERSANA’s best-in-class infrastructure and deep expertise in oncology commercialization. EVERSANA’s demonstrated ability to execute across the product lifecycle enhances our ability to scale efficiently, ensure timely market access for LYMPHIR, and support a high-quality launch aligned with investor expectations. We believe this collaboration strengthens our operational readiness, de-risks execution, and enhances our capacity to generate long-term value for shareholders.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month